The program was divided up
into 5 sessions –
=
Session 1 – Recent updates in NETs (ENETs 2018)
=
Session 2 – Radionuclide Therapies
=
Session 3 – Patient Outcomes / Personalised Medicine
=
Session 4 State of the Art
Management of NETs
=
Session 5 – Challenges in the
Patient Management of NET
The day was a wonderful opportunity to network with
the multidisciplinary team and to hear from International Specialists, Prof Kjell
Oberg and Prof Jonathan Strosberg (via webcast).
In session 1 Prof Oberg
discussed the NET test which is the circulating Neuroendocrine tumour signature
which is currently being trialed in London, Milan and Turin. The accuracy is
93% and results are available within 8 hours. There were updates on genomic
alterations, Terbium radionuclides for Theranostics and Immuno-oncology /
oncolytic viruses.
The sessions which followed were A/Prof Nat Lenzo presented
PRRT today including, new therapy, combination therapy, new WHO staging for G3
and Merkel Cell. Amos Hedt presented Copper Isotopes, the benefits of Copper 64
& 67, and Sartate radiopharmaceutical which has less decay and last longer.
Prof Dale Bailey discussed developing tools for practicing informed theranostics
which included Ga 67. Prof Eva Segelov highlighted the patient being the
central in focus Integrated Patient and Multidiscipinary Care.
Dr John Leyden
gave an overview of the patients experience which then led into A/Prof Nick
Pavlakis updating on Control NETs, the process for NET Centres of Excellence,
Dr Ben Lawrence and the use of Genomics. Other presentations were Medical
Oncology managing NETs, the role of surgery and radiation oncology. The last
session of the day included case studies with panel discussion and liver
directed therapies.
